Letter: Fatal aplastic anemia with piperacetazine therapy.
作者信息
Yeung K Y, Corn M
出版信息
Ann Intern Med. 1974 Sep;81(3):411. doi: 10.7326/0003-4819-81-3-411.
PMID:4152939
Abstract
摘要
相似文献
1
Letter: Fatal aplastic anemia with piperacetazine therapy.信函：哌普嗪治疗导致的致命性再生障碍性贫血。
Ann Intern Med. 1974 Sep;81(3):411. doi: 10.7326/0003-4819-81-3-411.
2
Letter: Piperacetazine-induced failure to ejaculate.
Can Psychiatr Assoc J. 1974 Jun;19(3):322-3. doi: 10.1177/070674377401900322.
3
Adverse reaction reporting and new antipsychotics.
Lancet. 1993 Dec 11;342(8885):1440. doi: 10.1016/0140-6736(93)92929-n.
4
Acquired aplastic anemia secondary to perphenazine.
Can J Clin Pharmacol. 1999 Autumn;6(3):169-71.
5
Incontinence after piperacetazine treatment.
Can Psychiatr Assoc J. 1973 Apr;18(2):173. doi: 10.1177/070674377301800220.
6
Clinical effectiveness of piperacetazine injection in schizophrenic patients: a controlled study.
Adv Biochem Psychopharmacol. 1974;9(0):691-9.
7
A long-term pilot study of pipothiazine palmitate in chronic schizophrenia.棕榈酸哌泊噻嗪治疗慢性精神分裂症的长期试点研究。
Curr Ther Res Clin Exp. 1972 Nov;14(11):696-706.
8
[Drugs and blood].
Schweiz Rundsch Med Prax. 1985 Jan 15;74(3):40-5.
9
Piperacetazine study in state hospital patients.在州立医院患者中进行的哌泊噻嗪研究。
J Med Assoc Ga. 1974 Dec;63(12):465-7.
10
Clinical experience with pipotiazine palmitate (19.552 R.P.) in Nordic countries. Report of a multicentre investigation.棕榈酸哌泊噻嗪（19.552 R.P.）在北欧国家的临床经验。一项多中心调查的报告。
Acta Psychiatr Scand Suppl. 1973;241:51-6. doi: 10.1111/j.1600-0447.1973.tb07042.x.
Zotero 插件